Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Acquired by Barclays PLC

Barclays PLC raised its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 8.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 278,067 shares of the company's stock after acquiring an additional 22,184 shares during the period. Barclays PLC owned approximately 0.19% of Denali Therapeutics worth $5,666,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Sterling Capital Management LLC boosted its stake in shares of Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock valued at $36,000 after purchasing an additional 1,516 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Denali Therapeutics by 30.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock valued at $77,000 after buying an additional 885 shares in the last quarter. KBC Group NV grew its stake in Denali Therapeutics by 75.8% in the 4th quarter. KBC Group NV now owns 6,334 shares of the company's stock worth $129,000 after acquiring an additional 2,731 shares in the last quarter. AlphaQuest LLC increased its position in shares of Denali Therapeutics by 177.1% during the fourth quarter. AlphaQuest LLC now owns 6,961 shares of the company's stock worth $142,000 after acquiring an additional 4,449 shares during the period. Finally, E Fund Management Co. Ltd. boosted its holdings in shares of Denali Therapeutics by 32.2% in the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after purchasing an additional 2,436 shares during the period. Institutional investors own 92.92% of the company's stock.

Analyst Ratings Changes

Several brokerages have weighed in on DNLI. HC Wainwright upped their target price on Denali Therapeutics from $80.00 to $87.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Cantor Fitzgerald raised shares of Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, February 11th. They issued a "buy" rating and a $31.00 price target for the company. The Goldman Sachs Group cut their price objective on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. Finally, Baird R W upgraded Denali Therapeutics to a "strong-buy" rating in a report on Tuesday, January 7th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, Denali Therapeutics currently has a consensus rating of "Buy" and a consensus price target of $37.57.

Denali Therapeutics Stock Performance

NASDAQ:DNLI traded up $0.25 during mid-day trading on Tuesday, hitting $16.50. 1,521,238 shares of the company's stock traded hands, compared to its average volume of 1,081,767. The company has a fifty day moving average of $14.85 and a 200 day moving average of $20.71. Denali Therapeutics Inc. has a twelve month low of $10.57 and a twelve month high of $33.33. The company has a market capitalization of $2.40 billion, a P/E ratio of -5.98 and a beta of 1.58.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.08. On average, research analysts expect that Denali Therapeutics Inc. will post -2.71 earnings per share for the current fiscal year.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.